bioMérieux Launches chromID™ Lmono, a Rapid All-in-One Solution for Listeria monocytogenes Testing

bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of chromID™ Lmono, a new chromogenic medium that enables the rapid enumeration, detection and presumptive identification of Listeria monocytogenes in food products and production environment samples. Both protocols are certified according to EN ISO 16140.

The chromID Lmono enumeration methods reduce product release time and bring cost effectiveness and flexibility to low counts.

• With chromID Lmono, the Listeria monocytogenes enumeration takes just one day for a confirmed result whereas the ISO method requires 4 days.
• Only one plate is necessary for the pour plate enumeration when using chromID Lmono medium in bottles. Surface enumeration is performed with one plate less than all the existing methods used for enumeration of low numbers (< 10CFU/g).
• On this new media, Listeria monocytogenes gives turquoise blue colonies with no associated halo, which facilitates reading.

For the detection of L. monocytogenes, chromID Lmono gives results in one day after enrichment for both negative and confirmed positive samples. The turquoise blue colonies with no associated halo also make it easy to read highly-contaminated samples.

About chromID
chromID Lmono is a new solution for pathogen testing in the chromID range, which includes: chromID Ottaviani Agosti, chromID E.coli O157:H7,  chromID Salmonella, chromID Sakazakii, chromID Vibrio and chromID Coli.

About Listeria monocytogenes
Listeria monocytogenes is a Gram positive, non spore-forming facultative anaerobic bacterium and is the causative agent of listeriosis. This illness may cause pathologies such as meningitis, septicaemia, encephalitis and abortions. Groups at risk include pregnant women, neonates, immunocompromised patients, and the elderly. Listeria. monocytogenes is widespread in the environment and is a potential risk when raw, partially processed, ready-to-eat and even some fermented foods are consumed.

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more
than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com.